Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
McKesson
Accenture
Argus Health
Cantor Fitzgerald
Julphar
McKinsey
QuintilesIMS
US Army

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR JAKAFI

« Back to Dashboard

Clinical Trials for Jakafi

Trial ID Title Status Sponsor Phase Summary
NCT01251965 Phase l/II Study of Ruxolitinib for Acute Leukemia Completed Incyte Corporation Phase 1/Phase 2 The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with acute leukemia and to learn if the study drug can help control the disease. The safety of the drug will also be studied.
NCT01251965 Phase l/II Study of Ruxolitinib for Acute Leukemia Completed M.D. Anderson Cancer Center Phase 1/Phase 2 The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with acute leukemia and to learn if the study drug can help control the disease. The safety of the drug will also be studied.
NCT01732445 Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis Active, not recruiting National Cancer Institute (NCI) Phase 2 This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.
NCT01732445 Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis Active, not recruiting Mayo Clinic Phase 2 This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.
NCT01751425 Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) Recruiting Incyte Corporation Phase 1/Phase 2 This is a 2 part study. The goal of the first part of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given with a TKI that you are already taking (such as gleevec, sprycel, or nilotinib) as part of your standard of care treatment. The goal of the second part of this study is to learn if this drug combination can help to control CML. Although you have a good response to therapy, the disease is still detectable at low levels (this is called "minimal residual disease"). Researchers believe that eliminating all detectable evidence of disease may decrease the chances that the leukemia will ever come back. The safety of the drug combination will also be studied in both parts. Ruxolitinib is designed to block a protein called Jak2 that may help keep some leukemia cells alive even with TKI therapy. Blocking this protein may cause the cells to die.
NCT01751425 Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) Recruiting M.D. Anderson Cancer Center Phase 1/Phase 2 This is a 2 part study. The goal of the first part of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given with a TKI that you are already taking (such as gleevec, sprycel, or nilotinib) as part of your standard of care treatment. The goal of the second part of this study is to learn if this drug combination can help to control CML. Although you have a good response to therapy, the disease is still detectable at low levels (this is called "minimal residual disease"). Researchers believe that eliminating all detectable evidence of disease may decrease the chances that the leukemia will ever come back. The safety of the drug combination will also be studied in both parts. Ruxolitinib is designed to block a protein called Jak2 that may help keep some leukemia cells alive even with TKI therapy. Blocking this protein may cause the cells to die.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Jakafi

Condition Name

Condition Name for Jakafi
Intervention Trials
Leukemia 8
Myelofibrosis 5
Secondary Myelofibrosis 2
Chronic Lymphocytic Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Jakafi
Intervention Trials
Leukemia 11
Primary Myelofibrosis 9
Leukemia, Lymphoid 6
Leukemia, Lymphocytic, Chronic, B-Cell 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Jakafi

Trials by Country

Trials by Country for Jakafi
Location Trials
United States 65
Canada 2
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Jakafi
Location Trials
Texas 12
Arizona 7
New York 5
California 4
Massachusetts 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Jakafi

Clinical Trial Phase

Clinical Trial Phase for Jakafi
Clinical Trial Phase Trials
Phase 2 18
Phase 1/Phase 2 7
Phase 1 7
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Jakafi
Clinical Trial Phase Trials
Recruiting 19
Not yet recruiting 10
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Jakafi

Sponsor Name

Sponsor Name for Jakafi
Sponsor Trials
Incyte Corporation 18
M.D. Anderson Cancer Center 10
National Cancer Institute (NCI) 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Jakafi
Sponsor Trials
Other 31
Industry 25
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Fish and Richardson
Chinese Patent Office
QuintilesIMS
Covington
Fuji
US Department of Justice
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.